Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial

BACKGROUND: There is a paucity of data on COVID-19 vaccines in people living with HIV-1, who could be at increased risk of severe illness and death from COVID-19. We evaluated the safety and immunogenicity of a Matrix-M adjuvanted recombinant spike protein nanoparticle COVID-19 vaccine (NVX-CoV2373;...

Descripción completa

Detalles Bibliográficos
Autores principales: Madhi, Shabir A, Moodley, Dhayendre, Hanley, Sherika, Archary, Moherndran, Hoosain, Zaheer, Lalloo, Umesh, Louw, Cheryl, Fairlie, Lee, Fouche, Leon Frederik, Masilela, Mduduzi S L, Singh, Nishanta, Grobbelaar, Coert, Ahmed, Khatija, Benadé, Gabriella, Bhikha, Sutika, Bhorat, As'ad Ebrahim, Bhorat, Qasim, Joseph, Natasha, Dheda, Keertan, Esmail, Aliasgar, Foulkes, Sharne, Goga, Ameena, Oommen Jose, Aylin, Kruger, Gertruida, Kalonji, Dishiki J, Lalloo, Natasha, Lombaard, Johan J, Lombard Koen, Anthonet, Kany Luabeya, Angelique, Mngqibisa, Rosie, Petrick, Friedrich G, Pitsi, Annah, Tameris, Michele, Thombrayil, Asha, Vollgraaff, Pieter-Louis, Cloney-Clark, Shane, Zhu, Mingzhu, Bennett, Chijioke, Albert, Gary, Faust, Emmanuel, Plested, Joyce S, Fries, Lou, Robertson, Andreana, Neal, Susan, Cho, Iksung, Glenn, Greg M, Shinde, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9045746/
https://www.ncbi.nlm.nih.gov/pubmed/35489376
http://dx.doi.org/10.1016/S2352-3018(22)00041-8

Ejemplares similares

Ejemplares similares